Cargando…

IMMU-04. TARGETING ALTERNATIVE SPLICING VARIANTS TO STIMULATE ANTI-TUMOR IMMUNITY IN A NOVEL SYNGENEIC MOUSE MODEL OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT

Juvenile presentation of HGG has been shown to frequently involve somatic mutations of the H3-3A gene, which encodes a histone H3 variant. To address the paucity of identified TSAs in DHG, we utilized a novel computational platform, Isoform peptides from RNA splicing for Immunotherapy target Screeni...

Descripción completa

Detalles Bibliográficos
Autores principales: Owens, Geoffrey, Pan, Yang, Treger, Janet, Contreras, Erick, Soto, Horacio, Armellini, Amber, Na, Brian, Liau, Linda, Prins, Robert, Xing, Yi, Wang, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259920/
http://dx.doi.org/10.1093/neuonc/noad073.191
_version_ 1785057745714544640
author Owens, Geoffrey
Pan, Yang
Treger, Janet
Contreras, Erick
Soto, Horacio
Armellini, Amber
Na, Brian
Liau, Linda
Prins, Robert
Xing, Yi
Wang, Anthony
author_facet Owens, Geoffrey
Pan, Yang
Treger, Janet
Contreras, Erick
Soto, Horacio
Armellini, Amber
Na, Brian
Liau, Linda
Prins, Robert
Xing, Yi
Wang, Anthony
author_sort Owens, Geoffrey
collection PubMed
description Juvenile presentation of HGG has been shown to frequently involve somatic mutations of the H3-3A gene, which encodes a histone H3 variant. To address the paucity of identified TSAs in DHG, we utilized a novel computational platform, Isoform peptides from RNA splicing for Immunotherapy target Screening (IRIS). The IRIS pipeline is designed to leverage large-scale cancer and normal transcriptomic data to identify peptide sequences that result from alternative splicing events that are highly enriched in cancer cells, and are predicted to bind the HLA class I alleles carried by the individual patient. To investigate whether peptide-pulsed dendritic cells (DC) together with checkpoint blockade might be a potential treatment modality for diffuse hemispheric glioma, H3 G34-mutant, we have developed a novel mouse model, and utilized a novel bioinformatics pipeline to identify tumor-associated peptide antigens. We used the RCAS/tv-A system to target the expression of H3/G34R and PDGF-B and to knock out p53 in neural progenitors in transgenic C57BL/6 neonatal mice. Three independent cell lines were obtained that expressed transcripts associated with oligodendrocyte and interneuron lineages, and formed lethal tumors after intracranial implantation. Implementing IRIS, we identified nonapeptides generated from alternative splicing of mRNAs that were highly enriched in the tumor transcriptomes of two H3/G34R patients, and predicted to bind the HLA-A*2:01 class I allele carried by these patients. Three of the candidate peptides were conserved in the mouse and also predicted to bind the H2-Kb MHC I allele carried by C57/BL6 mice. Using our syngeneic mouse model, we showed that DCs pulsed with these peptides together with anti-PD1 mAb provided a significant survival benefit compared with checkpoint inhibitor and DCs pulsed with peptides that were not predicted to bind the H2-Kb allele.
format Online
Article
Text
id pubmed-10259920
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102599202023-06-13 IMMU-04. TARGETING ALTERNATIVE SPLICING VARIANTS TO STIMULATE ANTI-TUMOR IMMUNITY IN A NOVEL SYNGENEIC MOUSE MODEL OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT Owens, Geoffrey Pan, Yang Treger, Janet Contreras, Erick Soto, Horacio Armellini, Amber Na, Brian Liau, Linda Prins, Robert Xing, Yi Wang, Anthony Neuro Oncol Final Category: Immunology/Immunotherapy - IMMU Juvenile presentation of HGG has been shown to frequently involve somatic mutations of the H3-3A gene, which encodes a histone H3 variant. To address the paucity of identified TSAs in DHG, we utilized a novel computational platform, Isoform peptides from RNA splicing for Immunotherapy target Screening (IRIS). The IRIS pipeline is designed to leverage large-scale cancer and normal transcriptomic data to identify peptide sequences that result from alternative splicing events that are highly enriched in cancer cells, and are predicted to bind the HLA class I alleles carried by the individual patient. To investigate whether peptide-pulsed dendritic cells (DC) together with checkpoint blockade might be a potential treatment modality for diffuse hemispheric glioma, H3 G34-mutant, we have developed a novel mouse model, and utilized a novel bioinformatics pipeline to identify tumor-associated peptide antigens. We used the RCAS/tv-A system to target the expression of H3/G34R and PDGF-B and to knock out p53 in neural progenitors in transgenic C57BL/6 neonatal mice. Three independent cell lines were obtained that expressed transcripts associated with oligodendrocyte and interneuron lineages, and formed lethal tumors after intracranial implantation. Implementing IRIS, we identified nonapeptides generated from alternative splicing of mRNAs that were highly enriched in the tumor transcriptomes of two H3/G34R patients, and predicted to bind the HLA-A*2:01 class I allele carried by these patients. Three of the candidate peptides were conserved in the mouse and also predicted to bind the H2-Kb MHC I allele carried by C57/BL6 mice. Using our syngeneic mouse model, we showed that DCs pulsed with these peptides together with anti-PD1 mAb provided a significant survival benefit compared with checkpoint inhibitor and DCs pulsed with peptides that were not predicted to bind the H2-Kb allele. Oxford University Press 2023-06-12 /pmc/articles/PMC10259920/ http://dx.doi.org/10.1093/neuonc/noad073.191 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Final Category: Immunology/Immunotherapy - IMMU
Owens, Geoffrey
Pan, Yang
Treger, Janet
Contreras, Erick
Soto, Horacio
Armellini, Amber
Na, Brian
Liau, Linda
Prins, Robert
Xing, Yi
Wang, Anthony
IMMU-04. TARGETING ALTERNATIVE SPLICING VARIANTS TO STIMULATE ANTI-TUMOR IMMUNITY IN A NOVEL SYNGENEIC MOUSE MODEL OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
title IMMU-04. TARGETING ALTERNATIVE SPLICING VARIANTS TO STIMULATE ANTI-TUMOR IMMUNITY IN A NOVEL SYNGENEIC MOUSE MODEL OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
title_full IMMU-04. TARGETING ALTERNATIVE SPLICING VARIANTS TO STIMULATE ANTI-TUMOR IMMUNITY IN A NOVEL SYNGENEIC MOUSE MODEL OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
title_fullStr IMMU-04. TARGETING ALTERNATIVE SPLICING VARIANTS TO STIMULATE ANTI-TUMOR IMMUNITY IN A NOVEL SYNGENEIC MOUSE MODEL OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
title_full_unstemmed IMMU-04. TARGETING ALTERNATIVE SPLICING VARIANTS TO STIMULATE ANTI-TUMOR IMMUNITY IN A NOVEL SYNGENEIC MOUSE MODEL OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
title_short IMMU-04. TARGETING ALTERNATIVE SPLICING VARIANTS TO STIMULATE ANTI-TUMOR IMMUNITY IN A NOVEL SYNGENEIC MOUSE MODEL OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
title_sort immu-04. targeting alternative splicing variants to stimulate anti-tumor immunity in a novel syngeneic mouse model of diffuse hemispheric glioma, h3 g34-mutant
topic Final Category: Immunology/Immunotherapy - IMMU
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259920/
http://dx.doi.org/10.1093/neuonc/noad073.191
work_keys_str_mv AT owensgeoffrey immu04targetingalternativesplicingvariantstostimulateantitumorimmunityinanovelsyngeneicmousemodelofdiffusehemisphericgliomah3g34mutant
AT panyang immu04targetingalternativesplicingvariantstostimulateantitumorimmunityinanovelsyngeneicmousemodelofdiffusehemisphericgliomah3g34mutant
AT tregerjanet immu04targetingalternativesplicingvariantstostimulateantitumorimmunityinanovelsyngeneicmousemodelofdiffusehemisphericgliomah3g34mutant
AT contreraserick immu04targetingalternativesplicingvariantstostimulateantitumorimmunityinanovelsyngeneicmousemodelofdiffusehemisphericgliomah3g34mutant
AT sotohoracio immu04targetingalternativesplicingvariantstostimulateantitumorimmunityinanovelsyngeneicmousemodelofdiffusehemisphericgliomah3g34mutant
AT armelliniamber immu04targetingalternativesplicingvariantstostimulateantitumorimmunityinanovelsyngeneicmousemodelofdiffusehemisphericgliomah3g34mutant
AT nabrian immu04targetingalternativesplicingvariantstostimulateantitumorimmunityinanovelsyngeneicmousemodelofdiffusehemisphericgliomah3g34mutant
AT liaulinda immu04targetingalternativesplicingvariantstostimulateantitumorimmunityinanovelsyngeneicmousemodelofdiffusehemisphericgliomah3g34mutant
AT prinsrobert immu04targetingalternativesplicingvariantstostimulateantitumorimmunityinanovelsyngeneicmousemodelofdiffusehemisphericgliomah3g34mutant
AT xingyi immu04targetingalternativesplicingvariantstostimulateantitumorimmunityinanovelsyngeneicmousemodelofdiffusehemisphericgliomah3g34mutant
AT wanganthony immu04targetingalternativesplicingvariantstostimulateantitumorimmunityinanovelsyngeneicmousemodelofdiffusehemisphericgliomah3g34mutant